scholarly journals Genetic Associations with Day +100 Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor (MUD) Blood and Marrow Transplantation (DISCOVeRY-BMT Study)

2018 ◽  
Vol 24 (3) ◽  
pp. S81-S82
Author(s):  
Abbas Rizvi ◽  
Ezgi Karaesmen ◽  
Leah Preus ◽  
Philip L. McCarthy ◽  
Marcelo C. Pasquini ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Unrelated Donor ◽  
Genetic Associations ◽  
Matched Unrelated Donor ◽  
Blood And Marrow Transplantation ◽  
Related Mortality

scholarly journals Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation

Blood ◽  
2018 ◽  
Vol 131 (22) ◽  
pp. 2490-2499 ◽  
Author(s):  
Qianqian Zhu ◽  
Li Yan ◽  
Qian Liu ◽  
Chi Zhang ◽  
Lei Wei ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Germ Line ◽  
Survival Outcomes ◽  
Unrelated Donor ◽  
Donor Blood ◽  
Matched Unrelated Donor ◽  
Blood And Marrow Transplantation ◽  
Key Points ◽  
Variant Genotype ◽  
Exome Chip

Key Points We conducted the first exome-wide association study between germ line variant genotype and survival outcomes after unrelated-donor BMT. A number of novel genes were found to significantly affect survival outcomes.

scholarly journals Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment

2018 ◽  
Vol 2 (15) ◽  
pp. 2020-2028 ◽  
Author(s):  
George E. Georges ◽  
Kris Doney ◽  
Rainer Storb
Keyword(s):  
Bone Marrow ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Severe Aplastic Anemia ◽  
Unrelated Donor ◽  
Line Treatment ◽  
First Line ◽  
Matched Unrelated Donor ◽  
First Line Treatment

Abstract Treatment of severe aplastic anemia has improved significantly over the past 4 decades. This review will summarize the key areas of progress in the use of allogeneic hematopoietic cell transplantation and nontransplant immunosuppressive therapy (IST) for the treatment of aplastic anemia and then summarize the recommendations for first-line treatment. Based on recent data, we argue that guidelines for the initial treatment of patients with newly diagnosed severe aplastic anemia require revision. At the time of diagnosis, before beginning treatment, HLA typing should be done to identify a marrow donor among family members or in the unrelated donor registries, and a marrow transplant should be considered first-line therapy. The priority order of donor source for bone marrow transplantation is: (1) HLA-identical sibling, (2) HLA-matched unrelated donor, and (3) HLA-haploidentical donor if an HLA-matched unrelated donor is not rapidly available. Each of these donor marrow sources may be preferable to nontransplant IST. We make this recommendation because of the long-term persistent risk for disease relapse and secondary myelodysplastic syndrome or acute myeloid leukemia with the use of nontransplant IST for patients with aplastic anemia. In contrast, marrow transplantation is associated with high cure rates of aplastic anemia and a relatively low risk for graft-versus-host disease, with many patients now living for decades without the risk for disease recurrence or the development of clonal disorders. Implementation of this first-line treatment strategy will provide patients with severe aplastic anemia the best chance of long-term disease-free survival.

scholarly journals Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration

2018 ◽  
pp. 1-7
Author(s):  
José Carnot Uria ◽  
Calixto Hernández Cruz ◽  
Jorge Muñío Perurena ◽  
Wilfredo Torres Yribar ◽  
Jesús Diego de la Campa ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Marrow Transplantation ◽  
Lymphoblastic Leukemia ◽  
Disease Relapse ◽  
Eligibility Criteria ◽  
University Of Illinois ◽  
Blood And Marrow Transplantation ◽  
Scientific Report ◽  
Related Mortality

Blood and marrow transplantation (BMT) has been performed in Cuba for over 30 years with limited resources and without international relationships. Researchers from University of Illinois at Chicago and Hermanos Ameijeiras Hospital (HAH) in Havana collaborated on retrospectively analyzing 101 consecutive patients with adult acute leukemia who received BMT at HAH from June 1986 to January 2016. Of these, 82 had acute myeloid leukemia (AML) and 19 had acute lymphoblastic leukemia (ALL). BMT eligibility criteria included prior morphologic complete remission, no severe comorbidities, and age between 16 and 60 years. Patients with an HLA-matched donor received an allogeneic BMT, whereas the others received an autologous BMT. All patients received fresh stem cells from marrow (80%) or mobilized peripheral blood (19%). Of 82 patients with AML, 35 received an allogeneic (AML-allo) and 47 an autologous (AML-auto) BMT. Both groups had comparable median age (37 years) and follow-up of survivors. Overall survival (OS) was 34% in AML-allo and 38% in AML-auto. The transplant-related mortality rate was 40% in AML-allo and 17% in AML-auto, whereas the relapse-related mortality rates were 25% and 40%, respectively. Of the 19 patients with ALL, six received an allogeneic transplant. Of these, transplant-related mortality occurred in one patient and three died after disease relapse (OS, 33%). Of 13 patients who received autologous transplants, transplant-related mortality occurred in three and six died after disease relapse (OS, 31%). To our knowledge, this is the first scientific report on BMT performed in patients with acute leukemia in Cuba. The collaboration between University of Illinois at Chicago and HAH will further develop capacity building in research and implementation of new diagnostic and therapeutic strategies in Cuba.

Sign in / Sign up

Export Citation Format

Share Document